Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04854980 · ClinicalTrials.gov registry record
Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients
A clinical trial, sponsored by University of Rochester.
- Completed
- Registry status
- 8
- Enrollment target
NCT04854980: Completed study, sponsored by University of Rochester.
NCT04854980 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04854980 has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
To explore the immune response to the COVID-19 vaccine in cancer patients and compare to the general population.
Primary Outcome
Vaccine response, as determined by blood concentrations of serum IgG reactive to the RBD domain of spike protein from the original SARS-CoV-2 virus will be measured by ELISA
Interventions
- OTHER Blood Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-08-03 |
| Est. Completion | 2024-07-23 |
What the finished NCT04854980 record still lists
NCT04854980 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood Sample is the first listed.
NCT04854980 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04854980 about?
NCT04854980 is a clinical study titled "Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients". To explore the immune response to the COVID-19 vaccine in cancer patients and compare to the general population.
What is the current status of trial NCT04854980?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2021-08-03. Estimated completion is 2024-07-23.
What interventions are being tested in trial NCT04854980?
The interventions under investigation include: Blood Sample (OTHER).
Who is sponsoring clinical trial NCT04854980?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI